from Market Design at http://bit.ly/2EiFG8b on May 19, 2019 at 12:09PM Gail Cornwall, who follows San Francisco schools, replies to a recent article in the NY Times: A cautionary tale about linking school choice and segregation "Late last month, New York Times’ national education reporter Dana Goldstein wrote about public school choice and segregated schools […]
from Social Science & Medicine at http://bit.ly/2JtJuHD on May 19, 2019 at 11:45AM Publication date: Available online 18 May 2019 Source: Social Science & Medicine Author(s): Sara Green, Annamaria Carusi, Klaus Hoeyer Abstract Politically authorized reports on personalized and precision medicine stress an urgent need for finer-grained disease categories and faster taxonomic revision, through integration […]
from Health Policy at http://bit.ly/2Jriadf on May 19, 2019 at 10:58AM Publication date: Available online 18 May 2019 Source: Health Policy Author(s): Cristóbal Cuadrado, Francisca Crispi, Matías Libuy, Gregory Marchildon, Camilo Cid
from Google Alert at http://bit.ly/2YAPxxK on May 19, 2019 at 12:49AM Nandini chose Health Economics after working in the rural areas of Telangana that have been facing the challenge of clean drinking water. “When my …
from The European Journal of Health Economics at http://bit.ly/2JtBhmM on May 18, 2019 at 06:48PM Abstract Background To date, a multi-country review evaluating the cost-of-illness (COI) studies from the Central and Eastern European (CEE) region has not yet been published. Our main objective was to provide a general description about published COI studies from CEE. […]
from Health Policy at http://bit.ly/2Q9XRBv on May 18, 2019 at 05:10PM Publication date: Available online 18 May 2019 Source: Health Policy Author(s): Alexander Roediger, Tim Wilsdon, Artes Haderi, Kathy Pendleton, Boris Azais Abstract There is widespread concern regarding the high price of innovative medicines and their impact on the sustainability of healthcare systems. However, the […]
from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2Qe0Bhs on May 18, 2019 at 04:57PM While therapies for nonalcoholic steatohepatitis (NASH) aren’t expected to reach the market until a couple years yet, payers have already expressed some concerns about efficacy and price, BioPharma Dive reports. According to the report, the first drugs to hit the market […]
